Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Genmab licenses GT43 cancer target from Ganymed

April 28, 2004

CV Therapeutics describes adenosine A3 agonists for cancer and neutropenia therapy

April 28, 2004

Novel BH3-derived proapoptotic peptides developed by Dana Farber researchers

April 28, 2004

New data on Fujisawa's histone deacetylase inhibitor FR-901228

April 28, 2004

Novel cytotoxic agent effective against chemotherapy-resistant ovarian carcinoma

April 28, 2004

Synthetic truncated PSP94 for metastatic hormone-resistant prostate cancer patients

April 28, 2004

Preclinical studies shed light on molecular pathways of p53

April 27, 2004

SuperGen to submit Dacogen NDA on rolling basis

April 27, 2004

New CDK inhibitors developed by Schering-Plough and Pharmacopeia team

April 27, 2004

Antitubulin agent effective against tumor growth in vivo

April 27, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
$Silhouette of head and brainwith fractal art$
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit
BioWorld
Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...